started · updated
Tarsus Pharmaceuticals to acquire Alkeus in up to $800 million deal
Eye‑drug maker Tarsus Pharmaceuticals announced a cash‑and‑stock acquisition of privately held Alkeus Pharmaceuticals valued at up to $800 million. The deal includes an upfront payment of about $450 million—$270 million in cash and $180 million in Tarsus common stock—and could provide Alkeus shareholders with up to $350 million more tied to regulatory approval, first commercial sale milestones and low‑single‑digit royalties on net sales.
The transaction adds Alkeus’s experimental oral therapy gildeuretinol (ALK‑001) for Stargardt disease, a rare inherited retinal disorder with no approved U.S. treatment. Stargardt disease, which often begins in childhood, progressively damages central vision and has been clinically diagnosed in more than 36,000 people in the United States. Tarsus said the drug targets toxic vitamin‑A dimers that damage retinal cells. Initial data from the ongoing late‑stage trial are expected in the second half of 2029. The acquisition is slated to close in 2026, subject to regulatory clearance. Tarsus shares fell about 3 % in pre‑market trading following the announcement.
Entities
Alkeus Pharmaceuticals · Stargardt disease · Tarsus Pharmaceuticals · gildeuretinol (ALK-001)